GlassScriptPhysician profile
Marc Kallinen
NPI 1184056640
$3,349.75
in general payments reported to CMS, 2019-2025
18 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $57.59 · 2021: $112 · 2022: $248 · 2023: $773 · 2024: $566 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,455.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $534.95 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $474.07 | 2023-2025 | Xiidra, Miebo, Infuse |
| Biotissue Holdings INC. | $407.74 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $385.18 | 2020-2025 | Acuvue |
| Alcon Vision LLC | $348.06 | 2019-2025 | Total30, Tryptyr, Precision7 |
| Oyster Point Pharma, INC. | $227.37 | 2023-2025 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $220.20 | 2019-2023 | |
| Ocular Therapeutix, INC. | $120.90 | 2024 | Dextenza |
| Hoffmann-La Roche Limited | $108.69 | 2019 | |
| Apellis Pharmaceuticals, INC. | $104.77 | 2023 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $96.56 | 2024-2025 | Xdemvy |
| Coopervision INC. | $94.85 | 2019-2024 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $90.42 | 2019 | |
| Visioneering Technologies, INC. | $47.83 | 2019 | |
| Shire North American Group INC | $38.41 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $25.43 | 2021 | |
| Abb Con-Cise Optical Group LLC | $13.23 | 2019 | |
| Eyevance Pharmaceuticals LLC | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Kallinen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.